Aarti Pharmalabs Limited
Aarti Pharmalabs Limited (AARTIPHARM.BO) Stock Competitors & Peer Comparison
See (AARTIPHARM.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AARTIPHARM.BO | ₹733.55 | +4.27% | 64.8B | 30.30 | ₹23.58 | +0.56% |
| SUNPHARMA.BO | ₹1,841.30 | -2.64% | 4.4T | 40.55 | ₹45.50 | +0.89% |
| SUNPHARMA.NS | ₹1,840.60 | -2.68% | 4.4T | 40.47 | ₹45.58 | +0.89% |
| DIVISLAB.NS | ₹6,756.50 | -1.48% | 1.8T | 73.84 | ₹93.27 | +0.44% |
| DIVISLAB.BO | ₹6,759.75 | -1.46% | 1.8T | 73.79 | ₹93.30 | +0.44% |
| TORNTPHARM.NS | ₹4,572.60 | +2.31% | 1.5T | 66.92 | ₹67.04 | +0.78% |
| TORNTPHARM.BO | ₹4,571.90 | +2.26% | 1.5T | 70.90 | ₹63.25 | +0.78% |
| DRREDDY.NS | ₹1,331.40 | +0.98% | 1.1T | 25.96 | ₹50.36 | +0.61% |
| DRREDDY.BO | ₹1,332.10 | +1.04% | 1.1T | 19.27 | ₹67.84 | +0.61% |
| ZYDUSLIFE.BO | ₹1,073.05 | +3.56% | 1T | 20.76 | ₹50.05 | +1.06% |
Stock Comparison
AARTIPHARM.BO vs SUNPHARMA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUNPHARMA.BO trades at ₹1,841.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUNPHARMA.BO's P/E ratio is 40.55. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUNPHARMA.BO's competition here
AARTIPHARM.BO vs SUNPHARMA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUNPHARMA.NS trades at ₹1,840.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUNPHARMA.NS's P/E ratio is 40.47. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUNPHARMA.NS's competition here
AARTIPHARM.BO vs DIVISLAB.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while DIVISLAB.NS trades at ₹6,756.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas DIVISLAB.NS's P/E ratio is 73.84. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check DIVISLAB.NS's competition here
AARTIPHARM.BO vs DIVISLAB.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while DIVISLAB.BO trades at ₹6,759.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas DIVISLAB.BO's P/E ratio is 73.79. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check DIVISLAB.BO's competition here
AARTIPHARM.BO vs TORNTPHARM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while TORNTPHARM.NS trades at ₹4,572.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas TORNTPHARM.NS's P/E ratio is 66.92. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to TORNTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check TORNTPHARM.NS's competition here
AARTIPHARM.BO vs TORNTPHARM.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while TORNTPHARM.BO trades at ₹4,571.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas TORNTPHARM.BO's P/E ratio is 70.90. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to TORNTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check TORNTPHARM.BO's competition here
AARTIPHARM.BO vs DRREDDY.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while DRREDDY.NS trades at ₹1,331.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas DRREDDY.NS's P/E ratio is 25.96. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check DRREDDY.NS's competition here
AARTIPHARM.BO vs DRREDDY.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while DRREDDY.BO trades at ₹1,332.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas DRREDDY.BO's P/E ratio is 19.27. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check DRREDDY.BO's competition here
AARTIPHARM.BO vs ZYDUSLIFE.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ZYDUSLIFE.BO has a market cap of 1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ZYDUSLIFE.BO trades at ₹1,073.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ZYDUSLIFE.BO's P/E ratio is 20.76. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ZYDUSLIFE.BO's competition here
AARTIPHARM.BO vs ZYDUSLIFE.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ZYDUSLIFE.NS has a market cap of 1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ZYDUSLIFE.NS trades at ₹1,072.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ZYDUSLIFE.NS's P/E ratio is 20.75. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ZYDUSLIFE.NS's competition here
AARTIPHARM.BO vs LUPIN.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while LUPIN.NS trades at ₹2,287.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas LUPIN.NS's P/E ratio is 19.61. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check LUPIN.NS's competition here
AARTIPHARM.BO vs LUPIN.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while LUPIN.BO trades at ₹2,291.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas LUPIN.BO's P/E ratio is 24.15. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check LUPIN.BO's competition here
AARTIPHARM.BO vs MANKIND.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while MANKIND.BO trades at ₹2,456.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas MANKIND.BO's P/E ratio is 53.60. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check MANKIND.BO's competition here
AARTIPHARM.BO vs MANKIND.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while MANKIND.NS trades at ₹2,457.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas MANKIND.NS's P/E ratio is 53.60. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check MANKIND.NS's competition here
AARTIPHARM.BO vs AUROPHARMA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AUROPHARMA.BO has a market cap of 850.7B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AUROPHARMA.BO trades at ₹1,453.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AUROPHARMA.BO's P/E ratio is 24.87. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AUROPHARMA.BO's competition here
AARTIPHARM.BO vs AUROPHARMA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AUROPHARMA.NS has a market cap of 850B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AUROPHARMA.NS trades at ₹1,454.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AUROPHARMA.NS's P/E ratio is 24.26. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AUROPHARMA.NS's competition here
AARTIPHARM.BO vs LAURUSLABS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, LAURUSLABS.NS has a market cap of 725.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while LAURUSLABS.NS trades at ₹1,356.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas LAURUSLABS.NS's P/E ratio is 86.12. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check LAURUSLABS.NS's competition here
AARTIPHARM.BO vs LAURUSLABS.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, LAURUSLABS.BO has a market cap of 725.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while LAURUSLABS.BO trades at ₹1,357.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas LAURUSLABS.BO's P/E ratio is 86.11. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check LAURUSLABS.BO's competition here
AARTIPHARM.BO vs ALKEM.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ALKEM.BO has a market cap of 646.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ALKEM.BO trades at ₹5,400.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ALKEM.BO's P/E ratio is 27.23. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ALKEM.BO's competition here
AARTIPHARM.BO vs ALKEM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ALKEM.NS has a market cap of 646.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ALKEM.NS trades at ₹5,400.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ALKEM.NS's P/E ratio is 27.29. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ALKEM.NS's competition here
AARTIPHARM.BO vs GLENMARK.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GLENMARK.BO has a market cap of 637.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GLENMARK.BO trades at ₹2,335.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GLENMARK.BO's P/E ratio is 59.85. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GLENMARK.BO's competition here
AARTIPHARM.BO vs GLENMARK.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GLENMARK.NS has a market cap of 637.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GLENMARK.NS trades at ₹2,337.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GLENMARK.NS's P/E ratio is 59.72. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GLENMARK.NS's competition here
AARTIPHARM.BO vs SUVENPHAR.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUVENPHAR.NS's competition here
AARTIPHARM.BO vs SUVENPHAR.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUVENPHAR.BO's competition here
AARTIPHARM.BO vs IPCALAB.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, IPCALAB.NS has a market cap of 406.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while IPCALAB.NS trades at ₹1,571.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas IPCALAB.NS's P/E ratio is 44.58. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check IPCALAB.NS's competition here
AARTIPHARM.BO vs IPCALAB.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, IPCALAB.BO has a market cap of 406.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while IPCALAB.BO trades at ₹1,573.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas IPCALAB.BO's P/E ratio is 44.62. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check IPCALAB.BO's competition here
AARTIPHARM.BO vs AJANTPHARM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AJANTPHARM.NS has a market cap of 388.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AJANTPHARM.NS trades at ₹3,081.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AJANTPHARM.NS's P/E ratio is 36.78. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AJANTPHARM.NS's competition here
AARTIPHARM.BO vs AJANTPHARM.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AJANTPHARM.BO has a market cap of 388B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AJANTPHARM.BO trades at ₹3,082.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AJANTPHARM.BO's P/E ratio is 38.29. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AJANTPHARM.BO's competition here
AARTIPHARM.BO vs JBCHEPHARM.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, JBCHEPHARM.BO has a market cap of 352.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while JBCHEPHARM.BO trades at ₹2,226.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas JBCHEPHARM.BO's P/E ratio is 49.46. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check JBCHEPHARM.BO's competition here
AARTIPHARM.BO vs JBCHEPHARM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, JBCHEPHARM.NS has a market cap of 352B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while JBCHEPHARM.NS trades at ₹2,228.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas JBCHEPHARM.NS's P/E ratio is 49.33. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to JBCHEPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check JBCHEPHARM.NS's competition here
AARTIPHARM.BO vs EMCURE.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, EMCURE.NS has a market cap of 324.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while EMCURE.NS trades at ₹1,738.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas EMCURE.NS's P/E ratio is 35.17. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check EMCURE.NS's competition here
AARTIPHARM.BO vs WOCKPHARMA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, WOCKPHARMA.NS has a market cap of 256B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while WOCKPHARMA.NS trades at ₹1,637.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas WOCKPHARMA.NS's P/E ratio is 120.63. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check WOCKPHARMA.NS's competition here
AARTIPHARM.BO vs WOCKPHARMA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, WOCKPHARMA.BO has a market cap of 256B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while WOCKPHARMA.BO trades at ₹1,639.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas WOCKPHARMA.BO's P/E ratio is 120.62. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check WOCKPHARMA.BO's competition here
AARTIPHARM.BO vs PEL.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check PEL.NS's competition here
AARTIPHARM.BO vs PPLPHARMA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, PPLPHARMA.NS has a market cap of 232.7B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while PPLPHARMA.NS trades at ₹179.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas PPLPHARMA.NS's P/E ratio is -71.69. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check PPLPHARMA.NS's competition here
AARTIPHARM.BO vs PPLPHARMA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, PPLPHARMA.BO has a market cap of 232.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while PPLPHARMA.BO trades at ₹179.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas PPLPHARMA.BO's P/E ratio is -71.63. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check PPLPHARMA.BO's competition here
AARTIPHARM.BO vs ASTRAZEN.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ASTRAZEN.BO has a market cap of 215.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ASTRAZEN.BO trades at ₹8,795.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ASTRAZEN.BO's P/E ratio is 106.71. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ASTRAZEN.BO's competition here
AARTIPHARM.BO vs ASTRAZEN.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ASTRAZEN.NS has a market cap of 214.7B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ASTRAZEN.NS trades at ₹8,800.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ASTRAZEN.NS's P/E ratio is 106.36. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ASTRAZEN.NS's competition here
AARTIPHARM.BO vs NEULANDLAB.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, NEULANDLAB.NS has a market cap of 214.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while NEULANDLAB.NS trades at ₹16,758.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas NEULANDLAB.NS's P/E ratio is 58.72. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check NEULANDLAB.NS's competition here
AARTIPHARM.BO vs NEULANDLAB.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, NEULANDLAB.BO has a market cap of 213.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while NEULANDLAB.BO trades at ₹16,742.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas NEULANDLAB.BO's P/E ratio is 58.67. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check NEULANDLAB.BO's competition here
AARTIPHARM.BO vs NATCOPHARM.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, NATCOPHARM.BO has a market cap of 209.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while NATCOPHARM.BO trades at ₹1,172.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas NATCOPHARM.BO's P/E ratio is 13.62. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check NATCOPHARM.BO's competition here
AARTIPHARM.BO vs NATCOPHARM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, NATCOPHARM.NS has a market cap of 209.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while NATCOPHARM.NS trades at ₹1,173.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas NATCOPHARM.NS's P/E ratio is 13.45. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check NATCOPHARM.NS's competition here
AARTIPHARM.BO vs GRANULES.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GRANULES.NS has a market cap of 186.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GRANULES.NS trades at ₹758.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GRANULES.NS's P/E ratio is 30.75. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GRANULES.NS's competition here
AARTIPHARM.BO vs ERIS.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ERIS.BO has a market cap of 186.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ERIS.BO trades at ₹1,352.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ERIS.BO's P/E ratio is 29.68. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ERIS.BO's competition here
AARTIPHARM.BO vs ERIS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ERIS.NS has a market cap of 186.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ERIS.NS trades at ₹1,353.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ERIS.NS's P/E ratio is 29.65. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ERIS.NS's competition here
AARTIPHARM.BO vs GRANULES.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GRANULES.BO has a market cap of 182.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GRANULES.BO trades at ₹758.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GRANULES.BO's P/E ratio is 33.42. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GRANULES.BO's competition here
AARTIPHARM.BO vs COHANCE.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, COHANCE.NS has a market cap of 160.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while COHANCE.NS trades at ₹434.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas COHANCE.NS's P/E ratio is 89.82. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check COHANCE.NS's competition here
AARTIPHARM.BO vs COHANCE.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, COHANCE.BO has a market cap of 160.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while COHANCE.BO trades at ₹434.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas COHANCE.BO's P/E ratio is 89.81. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check COHANCE.BO's competition here
AARTIPHARM.BO vs JUBLPHARMA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, JUBLPHARMA.NS has a market cap of 159.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while JUBLPHARMA.NS trades at ₹1,007.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas JUBLPHARMA.NS's P/E ratio is 36.98. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check JUBLPHARMA.NS's competition here
AARTIPHARM.BO vs JUBLPHARMA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, JUBLPHARMA.BO has a market cap of 159.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while JUBLPHARMA.BO trades at ₹1,007.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas JUBLPHARMA.BO's P/E ratio is 36.98. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check JUBLPHARMA.BO's competition here
AARTIPHARM.BO vs CAPLIPOINT.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, CAPLIPOINT.BO has a market cap of 154.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while CAPLIPOINT.BO trades at ₹2,075.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas CAPLIPOINT.BO's P/E ratio is 24.09. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check CAPLIPOINT.BO's competition here
AARTIPHARM.BO vs CAPLIPOINT.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, CAPLIPOINT.NS has a market cap of 154.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while CAPLIPOINT.NS trades at ₹2,077.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas CAPLIPOINT.NS's P/E ratio is 24.12. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check CAPLIPOINT.NS's competition here
AARTIPHARM.BO vs APLLTD.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, APLLTD.NS has a market cap of 148.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while APLLTD.NS trades at ₹762.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas APLLTD.NS's P/E ratio is 22.03. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check APLLTD.NS's competition here
AARTIPHARM.BO vs APLLTD.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, APLLTD.BO has a market cap of 148.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while APLLTD.BO trades at ₹762.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas APLLTD.BO's P/E ratio is 22.01. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check APLLTD.BO's competition here
AARTIPHARM.BO vs GLS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GLS.NS's competition here
AARTIPHARM.BO vs GLS.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GLS.BO's competition here
AARTIPHARM.BO vs ALIVUS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ALIVUS.NS has a market cap of 127.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ALIVUS.NS trades at ₹1,049.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ALIVUS.NS's P/E ratio is 22.62. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ALIVUS.NS's competition here
AARTIPHARM.BO vs ALIVUS.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ALIVUS.BO has a market cap of 127.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ALIVUS.BO trades at ₹1,048.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ALIVUS.BO's P/E ratio is 22.56. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ALIVUS.BO's competition here
AARTIPHARM.BO vs CAPPL.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check CAPPL.BO's competition here
AARTIPHARM.BO vs VIYASH.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, VIYASH.NS has a market cap of 107.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while VIYASH.NS trades at ₹260.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas VIYASH.NS's P/E ratio is 61.36. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check VIYASH.NS's competition here
AARTIPHARM.BO vs STAR.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, STAR.NS has a market cap of 106.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while STAR.NS trades at ₹1,188.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas STAR.NS's P/E ratio is 19.09. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check STAR.NS's competition here
AARTIPHARM.BO vs STAR.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, STAR.BO has a market cap of 106.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while STAR.BO trades at ₹1,189.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas STAR.BO's P/E ratio is 19.11. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check STAR.BO's competition here
AARTIPHARM.BO vs SHILPAMED.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SHILPAMED.NS has a market cap of 95.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SHILPAMED.NS trades at ₹512.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SHILPAMED.NS's P/E ratio is 43.38. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SHILPAMED.NS's competition here
AARTIPHARM.BO vs PGHL.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, PGHL.BO has a market cap of 92.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while PGHL.BO trades at ₹5,721.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas PGHL.BO's P/E ratio is 39.07. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check PGHL.BO's competition here
AARTIPHARM.BO vs PGHL.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, PGHL.NS has a market cap of 92.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while PGHL.NS trades at ₹5,726.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas PGHL.NS's P/E ratio is 38.96. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check PGHL.NS's competition here
AARTIPHARM.BO vs AKUMS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AKUMS.NS has a market cap of 79.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AKUMS.NS trades at ₹521.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AKUMS.NS's P/E ratio is 31.18. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AKUMS.NS's competition here
AARTIPHARM.BO vs SUDEEPPHRM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUDEEPPHRM.NS has a market cap of 76.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUDEEPPHRM.NS trades at ₹696.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUDEEPPHRM.NS's P/E ratio is 45.22. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUDEEPPHRM.NS's competition here
AARTIPHARM.BO vs SPARC.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SPARC.BO has a market cap of 68.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SPARC.BO trades at ₹233.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SPARC.BO's P/E ratio is 4.39. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SPARC.BO's competition here
AARTIPHARM.BO vs SPARC.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SPARC.NS has a market cap of 68.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SPARC.NS trades at ₹232.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SPARC.NS's P/E ratio is 4.38. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SPARC.NS's competition here
AARTIPHARM.BO vs AARTIPHARM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AARTIPHARM.NS has a market cap of 64.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AARTIPHARM.NS trades at ₹732.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AARTIPHARM.NS's P/E ratio is 30.28. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AARTIPHARM.NS's competition here
AARTIPHARM.BO vs SUVEN.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUVEN.BO has a market cap of 61.7B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUVEN.BO trades at ₹271.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUVEN.BO's P/E ratio is -21.61. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUVEN.BO's competition here
AARTIPHARM.BO vs FDC.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, FDC.BO has a market cap of 60.8B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while FDC.BO trades at ₹369.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas FDC.BO's P/E ratio is 28.12. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check FDC.BO's competition here
AARTIPHARM.BO vs FDC.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, FDC.NS has a market cap of 60.8B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while FDC.NS trades at ₹369.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas FDC.NS's P/E ratio is 28.04. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check FDC.NS's competition here
AARTIPHARM.BO vs SUVEN.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SUVEN.NS has a market cap of 59.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SUVEN.NS trades at ₹271.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SUVEN.NS's P/E ratio is -21.88. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SUVEN.NS's competition here
AARTIPHARM.BO vs SEQUENT.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SEQUENT.BO's competition here
AARTIPHARM.BO vs SEQUENT.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SEQUENT.NS's competition here
AARTIPHARM.BO vs INNOVACAP.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, INNOVACAP.NS has a market cap of 48.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while INNOVACAP.NS trades at ₹855.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas INNOVACAP.NS's P/E ratio is 34.44. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check INNOVACAP.NS's competition here
AARTIPHARM.BO vs SHILPAMED.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SHILPAMED.BO has a market cap of 48.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SHILPAMED.BO trades at ₹511.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SHILPAMED.BO's P/E ratio is 43.60. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SHILPAMED.BO's competition here
AARTIPHARM.BO vs GUJTHEM.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GUJTHEM.NS has a market cap of 40.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GUJTHEM.NS trades at ₹389.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GUJTHEM.NS's P/E ratio is 83.99. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GUJTHEM.NS's competition here
AARTIPHARM.BO vs RPGLIFE.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, RPGLIFE.BO has a market cap of 38B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while RPGLIFE.BO trades at ₹2,257.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas RPGLIFE.BO's P/E ratio is 18.77. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check RPGLIFE.BO's competition here
AARTIPHARM.BO vs RPGLIFE.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, RPGLIFE.NS has a market cap of 37.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while RPGLIFE.NS trades at ₹2,253.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas RPGLIFE.NS's P/E ratio is 18.71. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check RPGLIFE.NS's competition here
AARTIPHARM.BO vs ORCHPHARMA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ORCHPHARMA.BO has a market cap of 35.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ORCHPHARMA.BO trades at ₹715.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ORCHPHARMA.BO's P/E ratio is 188.80. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ORCHPHARMA.BO's competition here
AARTIPHARM.BO vs ORCHPHARMA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, ORCHPHARMA.NS has a market cap of 35.8B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while ORCHPHARMA.NS trades at ₹715.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas ORCHPHARMA.NS's P/E ratio is 188.40. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check ORCHPHARMA.NS's competition here
AARTIPHARM.BO vs AARTIDRUGS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AARTIDRUGS.NS has a market cap of 35.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AARTIDRUGS.NS trades at ₹394.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AARTIDRUGS.NS's P/E ratio is 17.64. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AARTIDRUGS.NS's competition here
AARTIPHARM.BO vs AARTIDRUGS.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, AARTIDRUGS.BO has a market cap of 35.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while AARTIDRUGS.BO trades at ₹394.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas AARTIDRUGS.BO's P/E ratio is 17.62. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check AARTIDRUGS.BO's competition here
AARTIPHARM.BO vs IOLCP.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, IOLCP.BO has a market cap of 34.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while IOLCP.BO trades at ₹124.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas IOLCP.BO's P/E ratio is 30.07. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check IOLCP.BO's competition here
AARTIPHARM.BO vs IOLCP.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, IOLCP.NS has a market cap of 34.9B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while IOLCP.NS trades at ₹124.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas IOLCP.NS's P/E ratio is 30.06. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check IOLCP.NS's competition here
AARTIPHARM.BO vs NOVARTIND.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, NOVARTIND.NS has a market cap of 33.7B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while NOVARTIND.NS trades at ₹1,360.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas NOVARTIND.NS's P/E ratio is 36.21. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check NOVARTIND.NS's competition here
AARTIPHARM.BO vs NOVARTIND.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, NOVARTIND.BO has a market cap of 33.6B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while NOVARTIND.BO trades at ₹1,361.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas NOVARTIND.BO's P/E ratio is 36.14. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check NOVARTIND.BO's competition here
AARTIPHARM.BO vs BLISSGVS.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, BLISSGVS.NS has a market cap of 31.8B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while BLISSGVS.NS trades at ₹317.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas BLISSGVS.NS's P/E ratio is 25.01. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check BLISSGVS.NS's competition here
AARTIPHARM.BO vs BLISSGVS.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, BLISSGVS.BO has a market cap of 31.8B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while BLISSGVS.BO trades at ₹317.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas BLISSGVS.BO's P/E ratio is 25.02. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check BLISSGVS.BO's competition here
AARTIPHARM.BO vs GUFICBIO.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GUFICBIO.NS has a market cap of 29.5B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GUFICBIO.NS trades at ₹325.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GUFICBIO.NS's P/E ratio is 58.74. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GUFICBIO.NS's competition here
AARTIPHARM.BO vs GUFICBIO.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, GUFICBIO.BO has a market cap of 29.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while GUFICBIO.BO trades at ₹326.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas GUFICBIO.BO's P/E ratio is 58.84. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check GUFICBIO.BO's competition here
AARTIPHARM.BO vs SOLARA.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SOLARA.BO has a market cap of 26.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SOLARA.BO trades at ₹555.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SOLARA.BO's P/E ratio is -114.31. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SOLARA.BO's competition here
AARTIPHARM.BO vs SOLARA.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, SOLARA.NS has a market cap of 26.4B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while SOLARA.NS trades at ₹554.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas SOLARA.NS's P/E ratio is -114.19. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, AARTIPHARM.BO is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check SOLARA.NS's competition here
AARTIPHARM.BO vs UNICHEMLAB.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, UNICHEMLAB.BO has a market cap of 26.2B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while UNICHEMLAB.BO trades at ₹361.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas UNICHEMLAB.BO's P/E ratio is 8.90. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check UNICHEMLAB.BO's competition here
AARTIPHARM.BO vs UNICHEMLAB.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, UNICHEMLAB.NS has a market cap of 26.1B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while UNICHEMLAB.NS trades at ₹359.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas UNICHEMLAB.NS's P/E ratio is 8.88. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check UNICHEMLAB.NS's competition here
AARTIPHARM.BO vs HIKAL.NS Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, HIKAL.NS has a market cap of 25.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while HIKAL.NS trades at ₹214.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas HIKAL.NS's P/E ratio is -193.72. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check HIKAL.NS's competition here
AARTIPHARM.BO vs HIKAL.BO Comparison May 2026
AARTIPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AARTIPHARM.BO stands at 64.8B. In comparison, HIKAL.BO has a market cap of 25.3B. Regarding current trading prices, AARTIPHARM.BO is priced at ₹733.55, while HIKAL.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AARTIPHARM.BO currently has a P/E ratio of 30.30, whereas HIKAL.BO's P/E ratio is 256.25. In terms of profitability, AARTIPHARM.BO's ROE is +0.11%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, AARTIPHARM.BO is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AARTIPHARM.BO.Check HIKAL.BO's competition here